Lack of Association between hOGG1 Ser326Cys Polymorphism and the Risk of Bladder Cancer: A Meta-Analysis

Objective: In some but not all studies, hOGG1 Ser326Cys polymorphism has been reported to contribute to the risk of bladder cancer. To determine whether there is a significant association of hOGG1 Ser326Cys polymorphism with the susceptibility for bladder cancer, we performed a comprehensive meta-analysis. Methods: The electronic PubMed, Medline and Springer databases were searched for publications on the association between hOGG1 Ser326Cys polymorphism and bladder cancer through to May 20, 2011. Seven case-control studies were identified, including 2,474 cases and 2,408 controls. From these identified publications, crude odds ratios (ORs) and 95% confidence intervals (Cis) were calculated to estimate the strength of association using fixedor random-effects models. Two investigators each extracted data and conducted the analysis independently. Results: Overall, no significant associations were found between hOGG1 Ser326Cys polymorphism and bladder cancer in co-dominant models (GG vs. CC: OR 1.11, 95% Cl 0.74-1.66, p = 0.63; GC vs. CC: OR 1.07,95% Cl 0.80-1.41, p = 0.65). Similarly, no significant associations with bladder cancer were observed in the recessive model (GG vs. GC+CC: OR 1.05, 95% Cl 0.65-1.70, p = 0.85), dominant model (GG+GC vs. CC: OR 1.07, 95% Cl 0.87-1.32, p = 0.53) and allele model (G vs. C: OR 1.06,95% Cl 0.90-1.26, p = 0.49). In the stratified analyses by ethnicity, control sources, pathology, Hardy-Weinberg equilibrium, significant associations were still not observed. Conclusions: The overall current literature on hOGG1 Ser326Cys polymorphism and the risk of bladder cancer suggests no statistically significant association between the two. Additional primary studies may be necessary to provide evidence of any significant association between this specific polymorphism and bladder cancer. Copyright (C) 2011 S. Karger AG, Basel